Multimutated herpes simplex virus G207 is a potent inhibitor of angiogenesis

Neoplasia

Volumn 6, Issue 6, 2004, Pages 725-735

  Cinatl Jr , Jindrich ^a   Michaelis, Martin ^a   Driever, Pablo Hernáiz ^b   Cinatl, Jaroslav ^a   Hrabeta, Jan ^c   Suhan, Tatyana ^a   Doerr, Hans Wilhelm ^a   Vogel, Jens Uwe ^a  

^a Institute of Medical Virology   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Angiogenesis; G207; HSV 1; Human rhabdomyosarcoma; Ribonucleotide reductase

Indexed keywords

MATRIGEL; ONCOLYTIC VIRUS;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASSAY; CANCER INHIBITION; CELL DESTRUCTION; CELL DIVISION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; ENDOTHELIUM CELL; EPITHELIUM CELL; FEMALE; FIBROBLAST; GLIA CELL; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MATRIGEL PLUG ASSAY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SKIN BLOOD VESSEL; TUMOR REGRESSION; TUMOR XENOGRAFT; UMBILICAL VEIN; VIRUS MUTATION;

EID: 11144341507     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.04265     Document Type: Article

References (46)

1. Kim D, Martuza RL, and Zwiebel J (2001). Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 7, 781-787.
2. Toda M, Rabkin SD, and Martuza RL (1998). Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther 9, 2177-2185.
3. Walker JR, McGeagh KG, Sundaresan P, Jorgensen TJ, Rabkin SD, and Martuza RL (1999). Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther 10, 2237-2243.
4. Kooby DA, Carew JF, Halterman MW, Mack JE, Bertino JR, Blumgart LH, Federoff HJ, and Fong Y (1999). Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J 13, 1325-1334.
5. Coukos G, Makrigiannakis A, Montas S, Kaiser LR, Toyozumi T, Benjamin I, Albelda SM, Rubin SC, and Molnar-Kimber KL (2000). Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy. Cancer Gene Ther 7, 275-283.
6. Chahlavi A, Todo T, Martuza RL, and Rabkin SD (1999). Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1, 162-169.
7. Todo T, Martuza RL, Rabkin SD, and Johnson PA (2001). Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA 98, 6396-6401.
8. Todo T, Rabkin SD, Chahlavi A, and Martuza RL (1999). Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy. Hum Gene Ther 10, 2869-2878.
9. Todo T, Rabkin SD, Sundaresan P, Wu A, Meehan KR, Herscowitz HB, and Martuza RL (1999). Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther 10, 2741-2755.
10. Bharatan NS, Currier MA, and Gripe TP (2002). Differential susceptibility of pediatric sarcoma cells to oncolysis by conditionally replication-competent herpes simplex viruses. J Pediatr Hematol Oncol 24, 447-453.
11. Cinatl J Jr, Cinatl J, Michaelis M, Kabickova H, Kotchetkov R, Vogel J-U, Doerr HW, Klingebiel T, and Hernáiz Driever P (2003). Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma. Cancer Res 63, 1508-1514.
12. Roizman B and Markovitz N (1997). Herpes simplex virus virulence: the functions of the gamma (1)34.5 gene. J Neurovirol 3, S1-S2.
13. Chou J, Kern ER, Whitley RJ, and Roizman B (1990). Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene non-essential for growth in culture. Science 250, 1262-1266.
14. Mineta T, Rabkin SD, and Martuza RL (1994). Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res 54, 3963-3966.
15. Goldstein DJ and Weller SK (1988). Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 62, 196-205.
16. Carroll NM, Chiocca EA, Takahashi K, and Tanabe KK (1996). Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann Surg 224, 323-329.
17. Mineta T, Rabkin SD, Yazaki T, Hunter WD, and Martuza RL (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1, 938-943.
18. Mohr I and Gluzman Y (1996). A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function. EMBO J 15, 4759-4766.
19. Folkman J (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med 285, 1182-1186.
20. Folkman J (1990). What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82, 4-6.
21. Miller KD, Sweeney CJ, and Sledge GW Jr (2001). Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 19, 1195-1206.
22. Kerbel R and Folkman J (2002). Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2, 727-739.
23. Michaelis M, Michaelis UR, Fleming I, Suhan T, Cinatl J, Blaheta RA, Hoffmann K, Kotchetkov R, Busse R, Nau H, and Cinatl J Jr (2004). Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol 65, 520-527.
24. Cinatl J Jr, Bittoova M, Margraf S, Vogel J-U, Cinatl J, Preiser W, and Doerr HW (2000). Cytomegalovirus infection decreases expression of thrombospondin-1 and -2 in cultured human retinal glial cells: effects of antiviral agents. J Infect Dis 182, 643-651.
25. Cinatl J Jr, Cinatl J, Hernáiz Driever P, Rabenau H, Hovak M, Benda R, Gümbel HO, Kornhuber B, and Doerr HW (1994). Induction of myogenic differentiation in a human rhabdomyosarcoma cell line by phenylacetate. Cancer Lett 78, 41-48.
26. Cinatl J Jr, Margraf S, Vogel J-U, Scholz M, Cinatl J, and Doerr HW (2001). Human cytomegalovirus circumvents NF-kappa B dependence in retinal pigment epithelial cells. J Immunol 167, 1900-1908.
27. Farassati F, Yang AD, and Lee PW (2001). Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol 3, 745-750.
28. LaVail JH, Topp KS, Giblin PA, and Garner JA (1997). Factors that contribute to the transneuronal spread of herpes simplex virus. J Neurosci Res 49, 485-496.
29. Hara M, Akasaka K, Akinaga S, Okabe M, Nakano H, Gomez R, Wood D, Uh M, and Tamanoi F (1993). Identification of Ras farnesyltransferase inhibitors by microbial screening. Proc Natl Acad Sci USA 90, 2281-2285.
30. Dudley DT, Pang L, Decker SJ, Bridges AJ, and Saltiel AR (1995). A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 92, 7686-7689.
31. Hoffbrand AV, Ganeshaguru K, Hooton JW, and Tattersall MH (1976). Effect of iron deficiency and desferrioxamine on DNA synthesis in human cells. Br J Haematol 33, 517-526.
32. Elford HL (1968). Effect of hydroxyurea on ribonucleotide reductase. Biochem Biophys Res Commun 33, 129-135.
33. Roizman B and Knipe DM (2001). Herpes simplex viruses and their replication. In Field's Virology (Vol. 2, 4th ed). Knipe DM and Howley PM (Eds). Lippincott, Philadelphia, PA, pp. 2399-2459.
34. Akhtar N, Dickerson EB, and Auerbach R (2002). The sponge/Matrigel angiogenesis assay. Angiogenesis 5, 75-80.
35. Auerbach R, Lewis R, Shinners B, Kubai L, and Akhtar N (2003). Angiogenesis assays: a critical overview. Clin Chem 49, 32-40.
36. Andreansky SS, He B, Gillespie GY, Soroceanu L, Markert J, Chou J, Roizman B, and Whitley RJ (1996). The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc Natl Acad Sci USA 93, 11313-11318.
37. He B, Gross M, and Roizman B (1997). The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1 alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 94, 843-848.
38. Bos JL (1989). ras oncogenes in human cancer: a review. Cancer Res 49, 4682-4689.
39. Wong CA, Jia W, and Matsubara JA (1999). Experimental gene therapy for an in vitro model of proliferative vitreoretinopathy. Can J Ophthalmol 34, 379-384.
40. Stanziale SF, Petrowsky H, Joe JK, Roberts GD, Zager JS, Gusani NJ, Ben Porat L, Gonen M, and Fong Y (2002). Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by up-regulating ribonucleotide reductase. Surgery 132, 353-359.
41. Petrowsky H, Roberts GD, Kooby DA, Burt BM, Bennett JJ, Delman KA, Stanziale SF, Delohery TM, Tong WP, Federoff HJ, and Fong Y (2001). Functional interaction between fluorodeoxyuridine-induced cellular alterations and replication of a ribonucleotide reductase-negative herpes simplex virus. J Virol 75, 7050-7058.
42. Reinblatt M, Pin RH, Federoff H, and Fong Y (2004). Utilizing tumor hypoxia to enhance oncolytic viral therapy in colorectal metastases. Ann Surg 239, 892-902.
43. Hunter WD, Martuza RL, Feigenbaum F, Todo T, Mineta T, Yazaki T, Toda M, Newsome JT, Platenberg RC, Manz HJ, and Rabkin SD (1999). Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J Virol 73, 6319-6326.
44. Sundaresan P, Hunter WD, Martuza RL, and Rabkin SD (2000). Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice. J Virol 74, 3832-3841.
45. Verheul HM, Voest EE, and Schlingemann RO (2004). Are tumours angiogenesis-dependent? J Pathol 202, 5-13.
46. Toyoizumi T, Mick R, Abbas AE, Kang EH, Kaiser LR, and Molnar-Kimber KL (1999). Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum Gene Ther 10, 3013-3029.